Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Company reports earnings and there is no mention of the ophthalmology and dermatology platform. Officially shelved?
Also, they let employees go who were working on those two platforms. In exchange, Geert Cauwenbergh was given a nice little going away present. What is wrong with that picture???
Did PHIO go private? NASDAQ compliance is a material event. Where is the PR?
Old news? It butchered the stock and continues to knee cap the company. Relevant facts.
Yeah, good points.
Carlton Johnson. No real bio experience. Ties to Eric Swartz that should disqualify him if his lack of experience didn’t. Failed business sitting at a penny. David Pohl: schleps 8-track tapes in another failed business but has direct ties to Eric Swartz. No real experience. Eric Swartz, owner of hedge fund that had off shore account playing the bounce back of PPHM share price. Let me know when you would like me to stop.
Anything can be made up and thrown in the kettle of soup. Even stones.
$500,000 a year as a BOD. Why no dirt on the old BOD? Shareholders who they stole money from should be outraged. And yet you make no mention of the corruption in the past. Now why is that?
I hope that was a typo. Sinking to new lows (yahoo lows!)
Steve King must be wondering what other opportunity is out there where he can bilk people out of hard earned money. Snake oil salesmen aided by modern technology and propaganda firms. Yay, the corrupt BOD are in the rear view. They should be in prison.
Will NASDAQ grant PHIO another extension? The hack management team at PHIO should not be allowed to reverse split. If NASDAQ offers the extension it should be on the grounds that PHIO cannot RS to remain compliant. That would be the responsible action taken by NASDAQ.
Geert has retired after destroying long term shareholder equity by about 99%. Who will be accountable going forward?
Board of directors who have NO oncology experience should resign immediately! With the change of company direction there is no need for them.
Let’s hope Tracy’s credibility can be upheld.
I would celebrate if we reach $10. It’s not my personal price target, but after the previous regime left the company on life support I would be satisfied.
This is now a brick and mortar company that is in a solidly growing market. No more pie in the sky dreams and conspiracy theories to excuse the ineptitude. It’s clear that Lias MUST perform.
I stopped reading fake news about Peregrine and Bavi far too late. $10 would get me excited now!
Nickel and dime fluctuation in price. Let me guess, we close at $4.27 again?
Go HALO!
Not that many years for me - only 8. But I hear ya! The positive is that institutional holding has never been this high. It shows a sign of confidence.
Lias is just another CEO mouthpiece. The folks behind the scenes are what is truly making the difference.
Most likely. We just need an event to create demand.
Nice to see we are over 60% institutional investment at this point. How much more is needed before any buying pressure sends the stock price north?
30:1 is what I remember the warrants to be (he asked for warrant conversion) not RS. I don’t have warrants and am opposed to companies using warrants as a funding mechanism.
At .03 or .05 per warrant they are essentially worthless and says there is no confidence PHIO will hit the target price in the given time. Don’t ask me what those are as I don’t know and prefer not to waste my time looking.
30:1 but I could be mistaken.
Nothole, I don’t want to dissuade you. I prefer good dialogue about PHIO. The questions/concerns I raise are ones I think the company needs to address sooner than later. Same with the ones sabaidii2 has brought to the board. He and I have had our jousting matches but we’ve both been misled by Geert Cauwenbergh.
I don’t know much about Glycostem but looking at their website, having a cartoon character mascot (see Scientific Advisors tab) seems unprofessional.
My question about these collaborations is who is paying for it? Or more precisely, what percentage is PHIO paying for? These private companies can feed off the publicly traded PHIO while they gain. PHIO shareholders get diluted more and more.
Call me cynical, but the hope that management has bought shares because they want to avoid or know the company will not reverse split the stock is just nonsense - especially in the case of Geert Cauwenbergh. That argument has been made far too often over the five-plus years I have been here.
Geert has told shareholders on conference calls and in emails that he is one of them because he, too, has purchased shares. Shortly after the stock gets split. The company was losing millions and he was rewarded a pay increase that more than covered his purchases. It was a bit insincere saying he, too, was a shareholder when it didn’t effect his income.
As much as I want the stock price up and to avoid another reverse split I am very wary of HCW minions trying to pump the stock after the $15 million placement.
Oh, and an underwriter selling $15 million of a biopharma company is not a highlight. Those “buyers” pump and dump through market manipulation. The discount was built into the deal and companies know to play along and release news as though it is special (aka the collaboration announcement on Thursday).
Unfortunately that Jan 7 slide is nearly three months old. Doesn’t seem like a long time but look how even the PR on Thursday begins to minimize the two platforms. No longer any discussion of partnering or sale. By the next earnings report dermatology and ophthalmology will no longer be in the headlines.
“The PHIO Management over the years has taken the NASD threat of NASDAQ Delisting very seriously and has always made big decisions to stay in compliance to maintain their NASDAQ LISTING.”
First off, PHIO only recently changed it’s name from RXi Pharmaceuticals. They maintain it was because of the decision to focus on immuno-oncology. One could argue they are trying to hide the past management debacles that led to two other RS.
Management may take the NASDAQ delisting threat seriously, but the only “big” decisions that were used were to reverse split. Twice in less than three years! Now faced with a third delisting threat, the only arrow in the quiver is ... wait for it ... to reverse split! They need to stop it. Management needs to stop taking the easy, less painful route of reverse splitting and start showing fiduciary responsibility. Shareholder value has been obliterated the past five years. With nothing on the short term horizon, hedge funds will continue to short the stock so another delisting notice will be given after the upcoming RS. The best thing the company can do is to delist and not get manipulated by hedge funds.
There is another hope. Bring to fruition Geert’s promises of partnering the dermal and ophthalmology. Notice how it was hardly mentioned in the latest earnings release. It gets pushed out further and further. Management wants shareholders to forget about It.
Two RS’s ago. Geert (former CEO) decided to shift business focus from the platform of dermatology and ophthalmology to now oncology. He made several promises of partnerships and a commercialized retail product for dermatology. To no avail. His failure to execute cost shareholders millions. Stock gets pummeled and after two RS’s drops to 30c. He buys boatloads of cheap shares and retires. Company changes name and collaborates with a European private company that has a cartoon character on the website.
The real gap is at $68.
No money in the collaboration. Company is side-skirting the dermatological and ophthalmology deals that were promised by Geert.
Alas, another company with a poster presentation. Ho hum. Very skeptical of the price move. Timing is just too similar to previous RS announcements.
Decent volume and continued price movement today. AH is good. But this is pennies. We need dimes.
The company has until May 13th to regain compliance. Ten consecutive days closing above $1.
Time is not on our side.
Not to be a wet blanket but this is very reminiscent of the weeks prior to the last RS and the one before that. The volume is high, whereas, the PPS rise is too soft. This will only reach $1 via RS. If Garret follows Geert’s lead it is bound to happen.
I am all in favor of delisting to avoid RS. F&$k The hedge funds who have manipulated RXII and now PHIO.
CDMOP (PPHMP) was designed to filter shareholder money directly to the overpaid former BOD. I recall some were touting the non-dilutive aspect of this instrument when it was first announced. Phtfff!
Anyone listen to the cc? Updates? I will listen at a later time but am curious if there were any highlights outside of what was posted in the PR.
Interesting that earnings will be prior to the bio services conference. Usually we wait until last day. Crossing my fingers that something could come out next week.
The purchase made by McCombs was all part of the scheme. Persuade shareholders to agree to the takeover , make a lot of money on the purchase, then unload before the share price gets tanked.
I think you have nailed it. I hope it’s not true - us shareholders of PPHM/CDMO have been victim to too much already.
That is an understatement! Peregrine was led by a fraudulent crew.
Blame it on Steve King and the old BOD for setting Roger up as it is. Another brilliant “management” move that we shareholders are continuing to pay for.
McCombs must have bought in this morning and then sold this afternoon with a decent profit. He’s good at buying low, selling high.
Not surprising. Perhaps why we are recovering today for no reason.